CD4+ T cell responses to SSX-4 in melanoma patients

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Synovial sarcoma X breakpoint (SSX) family genes are expressed in various human tumors, notably melanomas.
• SSX-encoded antigens (Ags) are tumor-specific, presenting potential targets for anticancer immunotherapy.
• CD4+ T cell responses are crucial in orchestrating adaptive immunity against cancer.

Purpose of the Study:

• To investigate CD4+ T cell responses against the SSX-4 antigen in melanoma patients.
• To identify specific SSX-4-derived antigenic sequences recognized by T cells.
• To evaluate the immunogenicity of the SSX-4 protein, particularly its N-terminal region.

Main Methods:

• In vitro stimulation of peripheral blood mononuclear cells (PBMC) from melanoma patients.
• Use of long peptides spanning the SSX-4 protein sequence for antigen stimulation.
• Detection and isolation of SSX-4-specific CD4+ T cells.
• Analysis of HLA class II restriction of T cell recognition.

Main Results:

• SSX-4-specific CD4+ T cells were detected and isolated from melanoma patients' PBMC.
• Multiple distinct antigenic sequences within SSX-4 were recognized by these T cells.
• The majority of identified T cell epitopes were located in the N-terminal Krüppel-associated box domain of SSX-4.
• T cell recognition was predominantly restricted by common HLA class II alleles.

Conclusions:

• Circulating lymphocytes in melanoma patients harbor CD4+ T cells specific for multiple SSX-4 sequences.
• The N-terminal region of SSX-4 demonstrates significant immunogenic potential.
• These findings support further investigation into SSX-4-specific T cell responses in cancer patients' disease progression.